{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-24-000108","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.106468+00:00","generated_at":"2026-05-31T02:22:04.081898+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Stockholders approve conversion of Series B Preferred at special meeting","bullets":["Special meeting held Sep 20, 2024; 75.9% of outstanding shares represented.","Proposal 1 passed: 12,514,261 FOR, 150,060 AGAINST, 1,650 abstentions (excluding 3,563,247 shares for Nasdaq compliance).","Proposal 2 (adjournment if needed) approved: 16,076,183 FOR, 151,789 AGAINST, 1,246 abstentions.","Approval allows issuance of common stock upon conversion of Series B Non-Voting Convertible Preferred."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-24-000108","json":"https://secwatch.observer/filing/0001453687-24-000108.json","markdown":"https://secwatch.observer/filing/0001453687-24-000108.md","text":"https://secwatch.observer/filing/0001453687-24-000108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000108/0001453687-24-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368724000108/rnac-20240920.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:22:04.081898+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}